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Abstract
Smoking behavior is a multifactorial phenotype with significant heritability. Identifying the specific loci that influence
smoking behavior could provide important etiological insights and facilitate the development of treatments to further
reduce smoking related mortality. Although several studies pointed to different candidate genes for smoking, there is still
a need for replication especially in samples from different countries. In the present study, we investigated whether 21
positive signals for smoking behavior from these studies are replicated in a sample of 531 blood donors from the Brazilian
population. The polymorphisms were chosen based on their representativeness of different candidate biologic systems,
strength of previous evidence, location and allele frequencies. By genotyping with the Sequenom MassARRAY iPLEX
platform and subsequent statistical analysis using Plink software, we show that two of the SNPs studied, in the SLC1A2
(rs1083658) and ACTN1 (rs2268983) genes, were associated with smoking behavior in our study population. These genes are
involved in crucial aspects of nicotine dependence, glutamate system and synaptic plasticity, and as such, are biologically
plausible candidates that merit further molecular analyses so as to clarify their potential role in smoking behavior.
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Introduction
Despite the well documented risks conferred by smoking,
cigarette smoking remains highly prevalent in many populations,
and continues to be the largest preventable cause of disease and
premature death worldwide. It is estimated that there are currently
over 1.3 billion smokers globally and that the number will grow to
1.6–1.9 billion by 2025 [1]. Nicotine is the main psychoactive
substance in tobacco that underpins smoking addiction, but
nicotine dependence (ND) reflects an interplay of neurobiological,
environmental and genetic factors [2]. Although the factors
influencing smoking behavior are complex, data from large-scale
population-based twin and family studies have established
significant impact of genetic factors on individual differences in
smoking behavior [3–5].
Identifying the specific loci that influence smoking behavior
could provide important etiological insights and facilitate the
development of treatments to further reduce smoking related
mortality. Linkage, gene association and genome-wide association
studies (GWAS) have identified many chromosomal regions and
genes associated with smoking behaviors. Some data have been
reproduced in multiple studies, but, in general, results of these
analyses have been inconclusive, with few loci replicated in
independent studies [6].
Among the genetic studies, candidate and genome-wide
association analyses have been the most widely-used strategy to
search for genes for nicotine dependence and other smoking-
related variables [7–11]. One of the strongest genetic associations
identified from such studies involves the CHRNA3-A5-B4 gene
cluster at chromosome 15 which encodes NAChR receptors [12].
Another association involves genes related to nicotine metabolism,
including the cytochrome P450 2A6 (CYP2A6) gene encoding
CYP2A6, an enzyme responsible primarily for nicotine metabo-
lism [13]. Associations of smoking behavior with the TTC12-
ANKK1-DRD2 gene cluster [14,15], which is functionally linked to
dopamine in the brain and with genes encoding glutamate
receptors (GRIN2B, GRIK2 and GRM8) and transporters
(SLC1A2), have also been reported [11,16–18]. This latter
association is consistent with increasing evidence for a crucial role
of glutamate in the brain reward system and with nicotine roles in
enhancing glutamate release and function [19].
These data have, however, been obtained primarily by studies
of European and North American populations and thus require
replication in other populations before general conclusions can be
drawn. We therefore assessed whether 21 of the SNPs identified in
prior studies as being associated with smoking behavior are
associated with smoking phenotypes also in the Brazilian
population. The fact that this sample is composed of Brazilians
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38666of European descent permits the inclusion of our data in future
meta-analysis.
Results
Characteristics of the study subject population are presented in
Table 1. As shown, the study subjects included 168 smokers and
363 non-smokers. Among the smokers, mean age of smoking onset
was 17 years old (6SD 4.0), average number of cigarettes smoked
per day was 14 (6SD 11.1), and Fagerstrom Test for Nicotine
Dependence (FTDN) levels ranged from medium to severe.
Among the non-smokers, there were more male than female
subjects and the percentage of subjects completing more than 11
years of schooling was higher than that of the smoking group
(39.7% vs. 32.1%, P=0.002). However, the non-smoking group
did not differ from the smoking group in relation to percentage of
individuals in stable martial relationships or employment status.
Results of genetic association data are shown in Table 2, with
allele frequencies for cases and controls indicated for all 21 SNPs
that passed all quality control criteria, including tests for Hardy–
Weinberg equilibrium. These analyses revealed smokers and non-
smokers to differ significantly in relation to the respective
frequencies of two SNPs, specifically, the rs10836358 SNP at the
SLC1A2 locus (P=0.047, OR=1.474) and the rs2268983 SNP at
the ACTN1 locus (P=0.033, OR=1.333). With respect to the
SLC1A2 rs10836358 SNP, presence of a T allele was associated
with a 1.474 times higher risk of being a smoker, while for the
ACTN1 rs2268983 SNP, the A allele was associated with 1.333
times higher risk for smoking. Since the proteins encoded by these
genes have potential influences on nicotine dependence, we also
tested for possible associations with FTDN scores, but results were
not significant.
For the remaining 19 SNPs, odds ratio ranged from 1.001
(rs4680 in COMT) to 1.328 (rs2237781 in GRM8), but no
statistically significant associations were detected.
Discussion
In this study, previously reported associations between smoking
behavior and SLC1A2 and ACTN1 genomic regions [11,20,21]
were confirmed in a Brazilian sample. These data provide the first
independent confirmation of these associations, suggesting that
these two genes may be physiologically and clinically relevant to
smoking behavior.
Nicotine is known to produce a variety of rewarding subjective
and cognitive effects [22]. However, the neurobiological mechan-
isms underlying nicotine actions are not well understood, involving
not only the direct action of nicotine at acetylcholine receptors, but
also other complex neurotransmitter pathways [20,23–26]. Neu-
rochemical studies have demonstrated that nicotine, at concentra-
tions achieved during smoking, can act at presynaptic receptors
[27] to enhance the release and function of glutamate. Glutamate
is the primary excitatory neurotransmitter in the brain [28].
Alterations in the glutamate uptake system may increase
extracellular glutamate levels and corresponding excitotoxicity
pathology [29]. Consistently with these findings, alterations in
glutamatergic neurotransmission are thought to be involved in
several neuropsychiatric disorders, such as schizophrenia, major
depressive and bipolar disorders and alcoholism [23,30].
Association between smoking behavior and the SLC1A2
genomic region has been previously reported [10,11]. This is in
agreement with a major role for the solute transporter protein
family member encoded by SLC1A2 in clearing glutamate from the
extracellular synaptic space in the central nervous system.
Association of the ACTN1 polymorphism rs2268983 with the
number of cigarettes smoked per day has also been previously
reported. The ACTN1 gene belongs to a superfamily that encodes
cytoskeletal-related proteins and has been implicated in synaptic
plasticity in mammalian brain [31]. Its association with smoking is
in keeping with the role of synaptic plasticity in the pathophys-
iology of addiction [32] and of actin-rich structures, such as
dendritic spines in regulation of postsynaptic signaling and
synaptic plasticity in the brain [33].
Therefore, the two loci replicated in our association study
correspond to highly plausible candidate genes for smoking
behavior. The proteins encoded by these genes have potential
individual influences on nicotine dependence, and may also have
interactive effects with other brain functions. Structural and
functional alterations of glutamatergic synapses, for example, may
be related to altered synaptic signaling and plasticity, mechanisms
that are generally involved in developmental, psychiatric, and
neurologic disorders, including nicotine addiction [34].
The present findings, however, have some limitations. The
study depends, for example, on the analysis of healthy young
Brazilian blood donors, but it is possible that other genes may
be more relevant in smokers ascertained from clinical or
psychiatric units. A bigger sample size would be desirable.
However, the study design and database are suitable for
inclusion in future meta-analysis. Also, it is possible that
a broader definition of smoking phenotypes might yield different
results, since some previous evidences of association were
restricted to other phenotypes. It is noteworthy that the fact
that positive signals were obtained even with smoking
phenotypes that are not exactly the same previously reported
might reinforce their position as interesting candidate regions.
We could not extend the analysis to other phenotypes for all
SNPs considering the lack of statistical power. However, despite
these caveats, the partial replication here of other association
data and the high biological plausibility of the two candidate
genes suggest that both genes should be further evaluated in
relation to smoking behavior, with a focus on defining
functional variants.
The current findings provide added evidence of the role for
genetics in nicotine dependence as is predicted by heritability
studies. Our findings also provide incentive for biologic analyses




Age 37.0 (11.9) 35.0 (11.6)
Cigarettes/day 14.1 (11.1) -
Age of smoking onset 17.0 (4.0) -
N (%)
Male* 86 (51.2) 228 (62.8)
Stable relationship 117 (69.6) 262 (72.2)
Employed 135 (80.4) 317 (87.3)
11+years of schooling** 54 (32.1) 144 (39.7)
FTDN (Moderate/Severe)*** 89 (53.6) -
*P=0.02.
**P=0.002.
***FTND=Fagerstrom Test for Nicotine Dependence: Moderate/High (4–10) vs
Low dependence nicotine level scores (0–3).
doi:10.1371/journal.pone.0038666.t001
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to specific smoking behaviors.
Materials and Methods
Samples
To carry out a case-control association study, 531 unrelated
study subjects were selected from blood donors who attended the
Sa ˜o Lucas Hospital of Pontifı ´cia Universidade Catolica do Rio
Grande do Sul (PUCRS) in Porto Alegre, Brazil, during the
period from March 2009 to August 2010. To be included in this
study, subjects had to be Brazilians of European descent between
the ages of 18 and 65 years. Former smokers and subjects
currently using any smoking cessation medication were excluded
from the study. All subjects completed a standardized self-report
questionnaire including demographic characteristics and smoking
history. Subjects were considered to be smokers if they smoked at
least 100 cigarettes over their lifetime and were smoking
regularly at the time of the study. Non smokers were defined
as individuals who had never smoked or who had smoked less
than 100 cigarettes in their lifetime [35].
Level of smoking severity in this sample was assessed using the
self-report six-item Fagerstro ¨m Test for Nicotine Dependence
(FTND), a test used widely to provide a quantitative de-
termination of nicotine dependence [36]. Individuals were
categorized into 2 levels based on a 0 to 10 scoring scale: low
nicotine dependence level (0 to 3) and moderate to severe
nicotine dependence level (4 to 10).
The study protocol was approved by the local ethics committee
and all subjects gave written informed consent. A summary of
demographic characteristics of this sample is provided in Table 1.
Genotyping
Survey for genes and SNPs was performed in available SNP
databases as well as genetics literature. Twenty one SNPs
(Table 3) were chosen based on the following criteria: (1) SNPs
should be in high priority candidate genes based on the
pathophysiology of smoking behaviors and location in replicated
chromosomal susceptibility regions by genome scan studies and
candidate gene studies; (2) previously reported smoking behavior-
associated genomic regions/SNPs; (3) minor allele frequency
(MAF) .20% for intronic SNPs and slightly lower (e.g., .10%
for coding SNPs in European population; (4) SNPs in the
putative promoter, 3’UTR and regulatory domain(s) within the
gene(s) as these could potentially impact gene expression and
protein stability. Regarding SLC1A2, one of the gene/SNP
included, GWAS studies have shown that it is promising
candidate gene and has been associated with smoking cessation.
However, these original studies reported other SNPs or only
mention the genomic region. The specific SNP (rs10836358) was
selected based on allele frequency and optimization to the
Sequenom MassARRAY iPLEX platform.
Genotyping was performed at the Mount Sinai Hospital/
University Health Network Gene Profiling Facility at Toronto,
Canada. Genomic DNA was extracted from whole blood using
the Herrmann and Frischau method [37]. Multiplex SNP assays
were designed using SpectroDesigner software, 5–10 ng DNA/
subject then amplified by PCR and primer extension products
Table 2. Genetic association data for 21 candidate SNPs for smoking behavior.
Gene SNP Chr Position Risk allele F_A F_U P OR
USH2A rs12126638 1 214242319 C 0.222 0.217 0.839 1.034
GRB14 rs4423615 2 165146476 G 0.519 0.474 0.182 1.199
NR3C2 rs5522 4 149576925 C 0.125 0.111 0.512 1.145
DRD1 rs4532 5 174802756 T 0.315 0.343 0.383 1.134
GRM6 rs2645339 5 178348669 G 0.494 0.485 0.802 1.034
GRM8 rs2237781 7 126462286 A 0.064 0.049 0.319 1.328
HTR5A rs6320 7 154493554 T 0.231 0.281 0.099 1.296
MSRA rs4509385 8 10217606 A 0.491 0.426 0.053 1.299
CDH23 rs10999845 10 72910367 A 0.203 0.217 0.602 1.090
ANKK1 rs4938015 11 112769854 C 0.345 0.362 0.593 1.078
BDNF rs6265 11 27636492 C 0.196 0.197 0.994 1.001
LUZP2 rs10834489 11 24794377 T 0.412 0.391 0.548 1.090
MICAL2 rs17477949 11 12175779 T 0.401 0.362 0.236 1.178
SLC1A2 rs10836358 11 35244076 T 0.124 0.173 0.047 1.474
GRIN2B rs7313149 12 13719554 C 0.181 0.158 0.357 1.178
ACTN1 rs2268983 14 68478450 A 0.543 0.471 0.033 1.333
TRIM9 rs8009082 14 50569094 C 0.198 0.201 0.910 1.019
CHRNA5 rs16969968 15 76669980 A 0.347 0.337 0.763 1.044
CAMKK1 rs758642 17 3733656 A 0.352 0.347 0.875 1.022
CABLES1 rs11082304 18 18974971 T 0.451 0.441 0.753 1.043
COMT rs4680 22 18331271 A 0.447 0.447 0.992 1.001
F_A: risk allele frequency in affected cases.
F_U: risk allele frequency in unaffected controls.
doi:10.1371/journal.pone.0038666.t002
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a deoxynucleotide and di-deoxynucleotide triphosphate cocktail.
Amplified DNA was then spotted onto a 384 SpectroChip and
analyzed using matrix-assisted laser desorption/ionization time-
of-flight (MALDI-TOF) mass spectrometry platform (Sequenom,
San Diego, CA).
Statistical Analysis
To control for genotyping quality, duplicate samples and
negative controls were included in the analysis and each SNP
had to pass the following criteria: (i) genotype missing rate
,10%, (ii) minor allele frequency .1% and (iii) Hardy-Weinberg
equilibrium of P.10
–4. Potential confounders (age, gender,
marital status, employment status, years of schooling) were
included as covariates using a statistical definition (association
with both the study factor and outcome for P,0.20) [38]. The
results were not significantly influenced by the adjustment. We
thus preferred to present unadjusted results for all SNPs in order
to make easier the comparability of findings with other studies
and inclusion in meta-analyses. Chi-square tests of allele and
genotype frequencies in cases and controls and testing of Hardy
Weinberg equilibrium for all individual SNPs were performed
using Plink (version 1.06) software. Significance level was set at
0.05.
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